Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
Daniela Paola Roggeri,1 Alessandro Roggeri,1 Elisa Rossi,2 Elisa Cinconze,2 Antonio Gasbarrini,3 PierAlessandro Monici Preti,4 Marisa De Rosa,2 1ProCure Solutions, Nembro, Bergamo, 2CINECA, Interuniversity Consortium, Bologna, 3Catholic University of Sacred Heart, Policlinic A Gemelli, Rome, 4Alfa W...
Main Authors: | Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-07-01
|
Series: | Hepatic Medicine : Evidence and Research |
Online Access: | http://www.dovepress.com/overt-hepatic-encephalopathy-in-italy-clinical-outcomes-and-healthcare-peer-reviewed-article-HMER |
Similar Items
-
Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy
by: Roggeri DP, et al.
Published: (2017-09-01) -
Impact of hospitalizations for bronchiolitis in preterm infants on long-term health care costs in Italy: a retrospective case-control study
by: Roggeri DP, et al.
Published: (2016-08-01) -
Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study
by: Roggeri A, et al.
Published: (2014-06-01) -
Venous tromboembolism treatment: budget impact analysis of rivaroxaban in Italy
by: Daniela Paola Roggeri, et al.
Published: (2014-12-01) -
Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues
by: Roggeri A, et al.
Published: (2016-03-01)